Preferred Label : HLA-A*0201-Restricted URLC10-VEGFR1-VEGFR2 Multipeptide Vaccine;
NCIt synonyms : HLA-A 0201-Restricted URLC10-VEGFR1-VEGFR2 Multipeptide Vaccine;
NCIt definition : A cancer vaccine containing three HLA-A*0201-restricted peptide epitopes with potential
immunostimulatory, antiangiogenic, and antitumor activities. Vaccine peptide epitopes
are derived from the tumor associated antigen (TAA) URLC (up-regulated in lung cancer
10) and vascular endothelial growth factor receptors (VEGFR) 1 and 2. Upon administration,
HLA-A*0201-restricted URLC10-VEGFR1-VEGFR2 multipeptide vaccine may stimulate a cytotoxic
T lymphocyte (CTL) response against URLC10-expressing tumor cells and the tumor microvasculature
expressing VEGFR 1 and 2 peptides; this may result in tumor cell lysis, the inhibition
of tumor angiogenesis, and decreased tumor growth. HLA-A*0201 is an MHC class I molecule
that presents antigenic peptides to CD8 T cells; epitope design restricted to epitopes
that bind most efficiently to HLA-A*0201 may improve antigenic peptide immunogenicity.;
NCI Metathesaurus CUI : CL383606;
Origin ID : C77900;
UMLS CUI : C2697542;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
